RBC Raises Price Target on NewAmsterdam Pharma to $51 From $47, Keeps Outperform, Speculative Risk

Summary

RBC Capital Markets raised its price target on NewAmsterdam Pharma to $51 from $47 while maintaining an Outperform rating, though noting speculative risk.